ArticlemedRxiv : the preprint server for health sciences2025
Protein risk scores enable precise prediction of cardiovascular events in chronic kidney disease patients.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenges of Biomarker Application in Patients with Cardiorenal Syndrome.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD). However, there is still a lack of reliable biomarkers to predict cardiovascular events (CVEs) in this population. Methods: This study aimed to develop a protein risk score (ProRS) model to predict CVEs in CKD patients. From the UK Biobank Pharma Proteomics Project (UKB-PPP), a total of 1,799 patients with CKD and no prior history of CVD were enrolled. Participants were randomly divided into a training set (70%) and an evaluation set (30%). We analyzed 2,920 plasma proteins to identify associations with CVEs, including coronary heart disease, heart failure, and ischemic stroke. Results: After adjusting for significant clinical factors, 38 proteins remained consistently significant in both the training and evaluation sets. Using an elastic net model, we selected 34 to construct the ProRS. The area under the receiver operating characteristics curve for annual CVEs prediction using the ProRS ranged from 0.67 to 0.74, compared to 0.60 to 0.69 for a clinical risk model, and 0.58 to 0.63 for a polygenic risk score. The 10-year incidence of CVEs among individuals in the top 5% of the ProRS distribution was 44.4%, significantly higher than 29.6% observed in the top 5% of the clinical risk model. Conversely, the bottom 5% of the ProRS group showed a 0% incidence rate, compared to 3.7% in the bottom 5% of the clinical risk model, demonstrating superior performance in both risk identification and exclusion. Notably, among patients classified as low risk by the clinical risk model, those with a high ProRS showed an increased risk of CVEs. In contrast, when the ProRS was low, the influence of the clinical risk model on event prediction was minimal. Mendelian randomization analysis identified 25 proteins whose levels were causally influenced by CKD, 10 of which were also associated with CVD. Conclusions: We demonstrated that plasma proteomics holds promise as a predictive biomarker for CVEs in patients with CKD. By enabling early identification of high-risk individuals, this approach may facilitate timely preventive interventions and ultimately reduce cardiovascular mortality in this vulnerable population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.